Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia

Objective Angiogenic factors are strongly associated with adverse maternal and fetal outcomes among women with preterm preeclampsia (PE) in developed countries. We evaluated the role of angiogenic factors and their relationship to adverse outcomes among Haitian women with PE. Material and Methods We measured plasma antiangiogenic soluble fms-like tyrosine kinase 1 (sFlt1) and proangiogenic placental growth factor (PlGF) levels in women with PE (n=35) compared to controls with no hypertensive disorders (NHD) (n=43) among subjects with singleton pregnancies that delivered at Hospital Albert Schweitzer (HAS) in Haiti. We divided the preeclamptic women into two groups, early onset (≤ 34 weeks) and late onset (>34 weeks) and examined relationships between sFlt1/PlGF ratios on admission and adverse outcomes (abruption, respiratory complications, stroke, renal insufficiency, eclampsia, maternal death, birth weight <2500 grams, or fetal/neonatal death) in women with PE subgroups as compared to NHD groups separated by week of admission. Data are presented as median (25th-75th centile), n (%), and proportions. Results Among patients with PE, most (24/35) were admitted at term. Adverse outcome rates in PE were much higher among the early onset group compared to the late onset group (100.0% vs. 54.2%, P=0.007). Plasma angiogenic factors were dramatically altered in both subtypes of PE. Angiogenic factors also correlated with adverse outcomes in both subtypes of PE. The median sFlt1/PlGF ratios for subjects with early onset PE with any adverse outcome vs. NHD <=34 weeks with no adverse outcome were 703.1 (146.6, 1614.9) and 9.6 (3.5, 58.6); P<0.001). Among late onset group the median sFlt1/PlGF ratio for women with any adverse outcome was 130.7 (56.1, 242.6) versus 22.4 (10.2, 58.7; P=0.005) in NHD >34 weeks with no adverse outcome. Conclusion PE-related adverse outcomes are common in women in Haiti and are associated with profound angiogenic imbalance regardless of gestational age at presentation.

[1]  E. Mcclure,et al.  Reducing Maternal Mortality From Preeclampsia and Eclampsia in Low-Resource Countries: What Should Work? , 2016 .

[2]  A. Shennan,et al.  Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. , 2015, Obstetrics and gynecology.

[3]  S. Rana,et al.  Adverse maternal and fetal outcomes and deaths related to preeclampsia and eclampsia in Haiti. , 2014, Pregnancy hypertension.

[4]  D. Wright,et al.  Competing Risks Model in Screening for Preeclampsia by Biophysical and Biochemical Markers at 30-33 Weeks' Gestation , 2014, Fetal Diagnosis and Therapy.

[5]  João Paulo Souza,et al.  Risk Factors of Pre-Eclampsia/Eclampsia and Its Adverse Outcomes in Low- and Middle-Income Countries: A WHO Secondary Analysis , 2014, PloS one.

[6]  E. Ota,et al.  Risk factors for spontaneous and provider‐initiated preterm delivery in high and low Human Development Index countries: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health , 2014, BJOG : an international journal of obstetrics and gynaecology.

[7]  H. Zeisler,et al.  New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia , 2014, Hypertension.

[8]  S. Karumanchi,et al.  Angiogenic factors in diagnosis, management, and research in preeclampsia. , 2014, Hypertension.

[9]  L. Mackillop,et al.  Diagnostic Accuracy of Placental Growth Factor in Women With Suspected Preeclampsia: A Prospective Multicenter Study , 2013, Circulation.

[10]  R. Romero,et al.  Preeclampsia: a link between trophoblast dysregulation and an antiangiogenic state. , 2013, The Journal of clinical investigation.

[11]  R. Romero,et al.  Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. , 2013, American journal of obstetrics and gynecology.

[12]  S. Maynard,et al.  Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[13]  K. Lim,et al.  Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia , 2012, Circulation.

[14]  R. Romero,et al.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia , 2011, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[15]  M. Merialdi,et al.  Pre-eclampsia in low and middle income countries. , 2011, Best practice & research. Clinical obstetrics & gynaecology.

[16]  A. Hingorani,et al.  Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension , 2010, Circulation.

[17]  J. Dudenhausen,et al.  An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. , 2010, American journal of obstetrics and gynecology.

[18]  R. Romero,et al.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia , 2009, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[19]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[20]  Wenjiang J. Fu,et al.  A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate , 2008, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[21]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia , 2007 .

[22]  B. Sibai,et al.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. , 2006, The New England journal of medicine.

[23]  J. Spencer-Jones,et al.  Make every mother and child count. , 2005, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[24]  R. Gaiser,et al.  Circulating Angiogenic Factors and the Risk of Preeclampsia , 2005 .

[25]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. , 2003, The Journal of clinical investigation.

[26]  Diagnosis and management of preeclampsia and eclampsia , 2002 .

[27]  S. Boccia,et al.  Pregnancy Hypertension : An International Journal of Women ’ s Cardiovascular Health , 2015 .

[28]  ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. , 2002, Obstetrics and gynecology.